Noiiglutide
Peptideexperimental
Clinical trial activity
12 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2012 (NCT02746302)
Timeline
Indications
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hs-20004
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06825416 | Phase 3 | Mar 14, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06649773 | Phase 3 | Oct 25, 2024 | Hengrui Therapeutics, Inc. |
| NCT06280768 | Phase 1 | Mar 1, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06137469 | Phase 1 | Dec 15, 2023 | Hengrui Therapeutics, Inc. |
| NCT05752461 | Phase 2 | Apr 12, 2023 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05333835 | Phase 2 | Jul 8, 2022 | Hengrui Therapeutics, Inc. |
| NCT05369767 | Phase 1 | May 24, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT04799327 | Phase 2 | Mar 29, 2021 | Hengrui Therapeutics, Inc. |
| NCT03848793 | Phase 2 | Mar 15, 2019 | Hengrui Therapeutics, Inc. |
| NCT02750007 | Phase 1 | Dec 1, 2015 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT02746315 | Phase 1 | Oct 1, 2014 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT02746302 | Phase 1 | Dec 1, 2012 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 5 | 5 | 3 | 2019 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 4 | 4 | 3 | 2022 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 1 | 2012 |
3 organizations
Page 1 / 1